Similar articles

• Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer.

  Pisansky TM. Pisansky TM. Urology. 2003 Dec 29;62 Suppl 1:36-45. doi: 10.1016/j.urology.2003.08.004. Urology. 2003. PMID: 14747040 Review.
• Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results.

  Zietman AL, Prince EA, Nakfoor BM, Shipley WU. Zietman AL, et al. Urology. 1997 Mar;49(3A Suppl):74-83. doi: 10.1016/s0090-4295(97)00173-8. Urology. 1997. PMID: 9123741 Review.
• Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy.

  Heyns CF. Heyns CF. Ann Oncol. 2010 Apr;21(4):903-904. doi: 10.1093/annonc/mdp554. Epub 2009 Nov 30. Ann Oncol. 2010. PMID: 19951953 No abstract available.
• External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.

  Koontz BF, Lee WR. Koontz BF, et al. Arch Esp Urol. 2011 Oct;64(8):858-64. Arch Esp Urol. 2011. PMID: 22052767 Review. English, Spanish.
• Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.

  Pienta KJ; Radiation Therapy Oncology Group P-0014. Pienta KJ, et al. Urology. 2003 Dec 29;62 Suppl 1:95-101. doi: 10.1016/j.urology.2003.10.001. Urology. 2003. PMID: 14747047 Clinical Trial.